ANAB: Held by 9 Biotech Hedge Funds (2026) | BiotechEdge

ANAB: Held by 9 Biotech Hedge Funds (2026) | BiotechEdge

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

Schmid John P.DirectorSaleApr 1, 2026SEC Filing →

Shares: 12,596Value: $701,706.79Price: $55.71

ANAB - Director Sale | Mixed Signal

Director Schmid sold 12,596 shares (~$702K) at $55.71, occurring ahead of near-term RA Phase 2 readout (Nov 29, 2024). The timing suggests either profit-taking post-run-up or caution on trial expectations, though without knowing his total holdings or historical trading patterns, the conviction signal is ambiguous. UC readout not due until Jan 2026, providing longer-term upside if RA data disappoints.

Schmid John P.DirectorSaleApr 1, 2026SEC Filing →

Shares: 7,527Value: $426,782.41Price: $56.70

ANAB Insider Sale - Timing Context

Director Schmid sold 7,527 shares ($426.8K) at $56.70, occurring ahead of the RA phase 2 readout (due 11/29). The sale size and timing relative to the near-term catalyst warrant monitoring, though director sales alone lack the conviction signal of insider buys. The UC readout in 1/26 provides a second data point for program validation.

Schmid John P.DirectorSaleApr 1, 2026SEC Filing →

Shares: 522Value: $29,962.23Price: $57.40

ANAB - Director Sale | Modest Negative Signal

Director Schmid sold 522 shares ($30k) ahead of near-term RA phase 2 readout (Nov 29, 2024), which could suggest lack of confidence in that catalyst or portfolio rebalancing given the higher-risk UC readout timing uncertainty (Jan 2026). The sale size is modest relative to typical director holdings, limiting conviction level, but the timing immediately before a binary event warrants monitoring.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 510Value: $28,872.63Price: $56.61

Daniel Faga sold 510 shares of ANAB for ~$28.9K, a negligible amount that likely reflects routine tax withholding or planned disposition rather than any directional signal. At just $28K, this is not a meaningful liquidity event for a CEO of a mid-cap biotech. No actionable read here absent a pattern of larger or accelerating sales.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 2,570Value: $148,819.19Price: $57.91

Faga sold a modest 2,570 shares at ~$57.91, a relatively small disposition for a CEO that likely reflects routine liquidity or tax-related planning rather than a directional signal. ANAB has had significant volatility tied to its immunology pipeline (rosnilimab, imsidolimab), so the size and timing should be weighed against any upcoming data readouts. This alone wouldn't warrant a bearish read, but worth monitoring if additional insiders begin selling or if the pace accelerates.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 3,662Value: $214,651.06Price: $58.62

Faga sold ~$215K in ANAB shares, a modest disposal for a CEO-level position. Without additional context—such as 10b5-1 plan participation, tax obligations, or upcoming option expirations—this is low-signal; routine liquidity sales by CEOs are common and this represents a small fraction of typical executive holdings. Worth monitoring for clustered insider selling or acceleration in pace, but standalone this doesn't warrant a directional read.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 490Value: $29,215.61Price: $59.62

Faga sold a very small block—490 shares totaling ~$29K—which is negligible relative to typical CEO-level holdings and likely represents routine tax withholding or planned disposition rather than a directional signal. At ~$60/share, ANAB is trading well off its highs, but the size here carries no meaningful informational content. No actionable read; monitor for larger or clustered insider activity.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 2,592Value: $164,203.98Price: $63.35

Faga sold a modest 2,592 shares (~$164K) at $63.35, a relatively small disposition for a CEO-level position. Without knowing his remaining holdings, this could easily represent routine liquidity, tax planning, or 10b5-1 plan execution rather than a directional signal. Worth monitoring for follow-on sales or whether this is an isolated event, but the size alone doesn't flag meaningful concern.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 3,155Value: $202,522.29Price: $64.19

Faga sold ~$203K in ANAB shares, a relatively modest disposal for a CEO-level position. Without additional context—such as 10b5-1 plan scheduling, options expiration, or personal liquidity needs—a single small sale from a biotech CEO is low-signal; it warrants monitoring but not alarm. Worth watching whether additional insider sales follow or if this remains isolated ahead of any upcoming clinical readouts.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 100Value: $6,599Price: $65.99

Insider Transaction Note — ANAB

CEO Daniel Faga sold just 100 shares (~$6,600 total), a negligible amount that almost certainly represents a tax withholding event or administrative transaction rather than a directional signal. At this size, this sale carries essentially zero informational value regarding management's outlook on AnaptysBio's pipeline or stock trajectory. Disregard as noise.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 550Value: $33,344.52Price: $60.63

Faga sold a modest 550 shares (~$33K) of ANAB at ~$60.63, a relatively small transaction for a CEO that likely reflects routine liquidity or tax-related planning rather than a directional signal. AnaptysBio's pipeline-stage valuation makes insider sales worth monitoring, but the size here is too small to indicate meaningful conviction against the stock. Would need to see clustering of insider sales or significantly larger volumes to flag this as actionable.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 1,012Value: $62,898.33Price: $62.15

Faga sold roughly $63K in ANAB stock — a modest amount for a CEO, likely reflecting routine liquidity or programmatic disposition rather than a directional signal. At just over 1,000 shares, this is too small to read as a meaningful change in conviction. Worth monitoring for pattern escalation but not actionable on its own.

Faga DanielPresident, CEOSaleMar 27, 2026SEC Filing →

Shares: 3,038Value: $198,072.13Price: $65.20

Faga sold ~$198K in ANAB stock, a relatively modest disposal for a CEO-level position. At ~$65/share, this is well off ANAB's historical highs, and the size suggests routine liquidity or tax planning rather than a bearish signal—worth monitoring whether this is part of a 10b5-1 plan. No red flag on its own, but would become notable if followed by additional insider selling ahead of clinical readouts.